Network pharmacology based pharmacokinetic assessment and evaluation of the therapeutic potential of catechin derivatives as a potential myostatin inhibitor: A special view on Sarcopenic Obesity

Abstract

Sarcopenic obesity has become a significant age-related metabolic problem. Catechins are flavanol, derivatives which poses a strong antioxidant activity. The major components of catechin derivatives. were identified through our physicochemical and pharmacokinetic parameters estimation. Therefore, in this study, network pharmacology was used to explore the multiple targets related to Sarcopenia, Metabolic syndrome, and obesity. The targets were identified from network analysis. The catechin derivatives were screened using Lipinski’s rule of five, Veber scale, Egan scale, and Muegge scale. From this drugglikness property catechin and Epicatechin was selected which were docked towards the myostatin inhibition PDB ID: 3HH2. Furthermore, the computational docking method on Catechin and Epicatechin with the stronger interaction towards myostatin inhibition receptor with the binding energy of −6.90 kcal/mol. and −7.0 kcal/mol from autodock software, respectively, for catechin and Epicatechin. Higher binding energy confirms the pharmacotherapeutic activity of Catechin and Epicatechin toward the myostatin inhibitor target.

Graphical Abstract

Keywords:

• Catechin
• Sarcopenia
• obesity
• molecular docking
• in silico

Acknowledgement

We would like to thank SRMIST for providing technical oriented sources.

Disclosure statement

No potential conflict of interest was reported by the authors.

Competing interests

The authors have no relevant financial or non-financial interests to disclose.

Consent to participate

Not applicable

Consent to publish

Not applicable

Ethics approval

Not applicable

Additional information

Funding

The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.